Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients.
Ouyang Y, Zhang W, Zhao Z, Wang C, Ren H, Xie J, Li X, Shen P, Shi H, Xu J, Xu Y, Wang W, Yang L, Yu X, Chen W, Zhao Y, Wang Z, Wu Y, Chen N, Pan X.
Ouyang Y, et al. Among authors: zhang w.
Clin Chim Acta. 2024 Mar 15;556:117851. doi: 10.1016/j.cca.2024.117851. Epub 2024 Mar 2.
Clin Chim Acta. 2024.
PMID: 38438007
Free article.